Schwab Joerg O, Gasparini Maurizio, Anselme Frédéric, Mabo Philippe, Peinado Rafael, Lavergne Thomas, Bocchiardo Mario, Mascioli Giosuè, Passardi Micaela, Mainardis Marc
Department of Medicine-Cardiology, University of Bonn, Bonn, Germany.
J Cardiovasc Electrophysiol. 2006 May;17(5):504-7. doi: 10.1111/j.1540-8167.2006.00433.x.
The purpose of this investigation is to compare the efficacy of antitachycardia pacing (ATP) delivered via the right ventricular (RV) lead versus ATP delivered simultaneously via the right and left ventricular leads (biventricular [BiV]) in the termination of ventricular tachyarrhythmia (VT) in patients receiving cardiac resynchronization therapy (CRT) with ICD capabilities.
The ADVANCE CRT is a prospective, multicenter, randomized, parallel trial evaluating RV versus BiV ATP in the termination of VT in CRT patients. The study will test the hypothesis that BiV ATP is superior to RV ATP in the termination of VT and fast VT. All patients with class I and IIa indications for an ICD implantation and CRT are included. The sample size has been estimated to 400 participants followed for 12 months to show a 10% benefit of BiV versus RV ATP. The efficacy of BiV ATP to terminate all VT presents the primary endpoint. The investigation is expected to be completed in 2007.
The ADVANCE CRT trial is the first large randomized clinical investigation evaluating the efficacy of BiV ATP in patients under CRT and ICD therapy.
本研究的目的是比较经右心室（RV）导线进行的抗心动过速起搏（ATP）与经右心室和左心室导线同时进行的ATP（双心室[BiV]）在终止具有植入式心脏复律除颤器（ICD）功能的心脏再同步治疗（CRT）患者的室性快速心律失常（VT）方面的疗效。
ADVANCE CRT是一项前瞻性、多中心、随机、平行试验，评估在CRT患者中RV与BiV ATP终止VT的效果。该研究将检验BiV ATP在终止VT和快速VT方面优于RV ATP的假设。纳入所有具有I类和IIa类ICD植入和CRT适应证的患者。样本量估计为400名参与者，随访12个月，以显示BiV与RV ATP相比有10%的益处。BiV ATP终止所有VT的疗效为主要终点。预计该研究将于2007年完成。
ADVANCE CRT试验是首个评估BiV ATP在CRT和ICD治疗患者中疗效的大型随机临床研究。
Zotero 插件